Sphingosine-1-phosphate is a signaling essential to immune cell migration, where SPNS2 exported S1P guides the trafficking of leukocytes out of lymphoid organs. Consequently, S1P signaling is targeted by several drugs to treat autoimmune diseases. A new paper from the Dürr and Sauer group reveals the unexpected regulation of SPNS2 by the intracellular signal PIP2, and suggests a novel pathway for autoimmune and immunooncology treatments. This work results from a very successful collaboration with the labs of Carol Robinson of Oxford's Kavli Institute for Nanoscience Discovery and Syma Khalid of Oxford's Department of Biochemistry.
https://doi.org/10.1016/j.molcel.2023.06.033
